|
US6258360B1
(en)
*
|
1989-05-04 |
2001-07-10 |
Igen International, Inc. |
Prodrugs activated by targeted catalytic proteins
|
|
US5527782A
(en)
*
|
1990-03-13 |
1996-06-18 |
Acic (Canada) Inc. |
5-halo-2,3'-O-cyclocytidines
|
|
AU671491B2
(en)
*
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
|
TW254946B
(xx)
*
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
|
US5476932A
(en)
*
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
|
IT1291983B1
(it)
*
|
1997-05-23 |
1999-01-25 |
Pro Bio Sint Srl |
Prodcedimento per la preparazione di un derivato della desossiuridina
|
|
NZ330360A
(en)
*
|
1997-06-02 |
1999-03-29 |
Hoffmann La Roche |
5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
|
|
EP0882734B1
(en)
*
|
1997-06-02 |
2009-08-26 |
F. Hoffmann-La Roche Ag |
5'-Deoxy-cytidine derivatives
|
|
US6005098A
(en)
*
|
1998-02-06 |
1999-12-21 |
Hoffmann-La Roche Inc. |
5'deoxycytidine derivatives
|
|
US20080113025A1
(en)
*
|
1998-11-02 |
2008-05-15 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
|
US20010051348A1
(en)
*
|
2000-01-28 |
2001-12-13 |
Lee Chee Wee |
Novel ligands and methods for preparing same
|
|
SE0102764D0
(sv)
|
2001-08-17 |
2001-08-17 |
Astrazeneca Ab |
Compounds
|
|
EP2316468A1
(en)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Delivery system and methods for protecting and administering dextroamphetamine
|
|
US6774758B2
(en)
*
|
2002-09-11 |
2004-08-10 |
Kalyan P. Gokhale |
Low harmonic rectifier circuit
|
|
GB0226930D0
(en)
|
2002-11-19 |
2002-12-24 |
Astrazeneca Ab |
Chemical compounds
|
|
EP1631278A4
(en)
*
|
2003-05-20 |
2006-09-20 |
Aronex Pharmaceuticals Inc |
COMBINED CHEMOTHERAPY COMPRISING CAPECITABINE AND A COMPLEX BASED ON LIPOSOMIC PLATINUM
|
|
ATE402185T1
(de)
*
|
2003-12-22 |
2008-08-15 |
Hoffmann La Roche |
Verfahren für fluorcytidinderivate
|
|
CA2554686A1
(en)
*
|
2004-02-18 |
2005-09-01 |
Astrazeneca Ab |
Compounds
|
|
AU2005214132B9
(en)
*
|
2004-02-18 |
2009-06-25 |
Astrazeneca Ab |
Benzamide derivatives and their use as glucokinae activating agents
|
|
CN100383128C
(zh)
*
|
2004-02-23 |
2008-04-23 |
上海迪赛诺医药发展有限公司 |
N4-氧羰基胞嘧啶衍生物及制备方法与应用
|
|
TW200600086A
(en)
|
2004-06-05 |
2006-01-01 |
Astrazeneca Ab |
Chemical compound
|
|
KR101061850B1
(ko)
|
2004-09-08 |
2011-09-02 |
삼성전자주식회사 |
박막 트랜지스터 표시판 및 그 제조방법
|
|
GB0421294D0
(en)
*
|
2004-09-24 |
2004-10-27 |
Angiogene Pharm Ltd |
Bioreductively-activated prodrugs
|
|
MX2007004560A
(es)
|
2004-10-16 |
2007-06-08 |
Astrazeneca Ab |
Proceso para hacer compuestos de fenoxi benzamida.
|
|
GB0423043D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
|
CN113952459B
(zh)
|
2005-02-03 |
2025-02-11 |
综合医院公司 |
治疗吉非替尼耐药性癌症的方法
|
|
NO322682B1
(no)
*
|
2005-03-18 |
2006-11-27 |
Clavis Pharma Asa |
Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
|
|
EP1868608A2
(en)
*
|
2005-04-01 |
2007-12-26 |
F. Hoffmann-Roche AG |
Method for administration of capecitabine
|
|
EP1891069A1
(en)
*
|
2005-05-24 |
2008-02-27 |
AstraZeneca AB |
2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
|
|
TW200714597A
(en)
|
2005-05-27 |
2007-04-16 |
Astrazeneca Ab |
Chemical compounds
|
|
EP2027113A1
(en)
*
|
2005-07-09 |
2009-02-25 |
AstraZeneca AB |
Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
|
|
JP2009500442A
(ja)
*
|
2005-07-09 |
2009-01-08 |
アストラゼネカ アクチボラグ |
2型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての2−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
|
|
KR20110084339A
(ko)
|
2005-07-09 |
2011-07-21 |
아스트라제네카 아베 |
당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
|
|
CN100569790C
(zh)
*
|
2005-07-15 |
2009-12-16 |
上海奥锐特国际贸易有限公司 |
合成n4-酰基-5'-脱氧-5-氟胞苷衍生物的方法
|
|
US20080292729A1
(en)
*
|
2005-07-21 |
2008-11-27 |
Nuvo Research Inc. |
Stabilized Chlorite Solutions in Combination with Fluoropyrimidines for Cancer Treatment
|
|
US9202182B2
(en)
*
|
2005-08-11 |
2015-12-01 |
International Business Machines Corporation |
Method and system for analyzing business architecture
|
|
CN103110948A
(zh)
|
2005-11-04 |
2013-05-22 |
惠氏公司 |
mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
|
|
TW200738621A
(en)
|
2005-11-28 |
2007-10-16 |
Astrazeneca Ab |
Chemical process
|
|
US20080085310A1
(en)
*
|
2006-10-06 |
2008-04-10 |
Maria Oksana Bachynsky |
Capecitabine rapidly disintegrating tablets
|
|
TW200825063A
(en)
|
2006-10-23 |
2008-06-16 |
Astrazeneca Ab |
Chemical compounds
|
|
CL2007003061A1
(es)
|
2006-10-26 |
2008-08-01 |
Astrazeneca Ab |
Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
|
|
CN100425617C
(zh)
*
|
2006-10-31 |
2008-10-15 |
浙江海正药业股份有限公司 |
一种含氟嘧啶类化合物烷氧羰酰化的方法
|
|
WO2008075073A1
(en)
|
2006-12-21 |
2008-06-26 |
Astrazeneca Ab |
Novel crystalline compound useful as glk activator
|
|
ITMI20070435A1
(it)
|
2007-03-05 |
2008-09-06 |
Innovate Biotechnology Srl |
2',3'-di-o-acil-5-fluoronucleosidi
|
|
BRPI0810067A2
(pt)
*
|
2007-04-20 |
2014-10-21 |
Reddys Lab Ltd Dr |
Processo para a preparação de capecitabina
|
|
EP2164856A1
(en)
*
|
2007-06-01 |
2010-03-24 |
Synthon B.V. |
Processes related to making capecitabine
|
|
WO2009042064A2
(en)
|
2007-09-21 |
2009-04-02 |
Nektar Therapeutics Al, Corporation |
Oligomer-nucleoside phosphate conjugates
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
WO2009088989A1
(en)
*
|
2008-01-03 |
2009-07-16 |
Plus Chemicals, S.A. |
Process for the preparation of capecitabine
|
|
CN102641270A
(zh)
|
2008-06-17 |
2012-08-22 |
惠氏有限责任公司 |
含有hki-272和长春瑞滨的抗肿瘤组合
|
|
HUE032958T2
(hu)
|
2008-08-04 |
2017-11-28 |
Wyeth Llc |
4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi
|
|
EP2324028A2
(en)
|
2008-08-04 |
2011-05-25 |
AstraZeneca AB |
Therapeutic agents 414
|
|
WO2010065586A2
(en)
*
|
2008-12-02 |
2010-06-10 |
Dr. Reddy's Laboratories Ltd. |
Preparation of capecitabine
|
|
EP2393472B1
(en)
*
|
2008-12-05 |
2019-06-05 |
NanoMed Holdings Pty Ltd |
Amphiphile prodrugs
|
|
CN101787066B
(zh)
*
|
2009-01-23 |
2013-07-31 |
高峰 |
阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
|
|
GB0902434D0
(en)
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Chemical process
|
|
GB0902406D0
(en)
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Crystalline polymorphic form
|
|
LT3000467T
(lt)
|
2009-04-06 |
2023-04-11 |
Wyeth Llc |
Krūties vėžio gydymo schema naudojant neratinibą
|
|
AR076221A1
(es)
*
|
2009-04-09 |
2011-05-26 |
Astrazeneca Ab |
Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
|
|
WO2010116177A1
(en)
|
2009-04-09 |
2010-10-14 |
Astrazeneca Ab |
A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
|
|
CN101875680B
(zh)
*
|
2009-04-28 |
2012-07-25 |
上海信旗医药科技有限公司 |
一种核苷类化合物及其制备方法和应用
|
|
KR20120037932A
(ko)
*
|
2009-07-23 |
2012-04-20 |
시노팜 타이완 리미티드 |
플루오로시티딘 유도체를 제조하는 방법
|
|
PL3117709T3
(pl)
|
2010-03-12 |
2019-01-31 |
Genzyme Corporation |
Terapia skojarzona do leczenia raka piersi
|
|
HK1206601A1
(en)
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
CN104411338A
(zh)
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
EP2900657B1
(en)
*
|
2012-09-26 |
2020-03-11 |
F.Hoffmann-La Roche Ag |
Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
|
|
CA2890359A1
(en)
*
|
2012-11-07 |
2014-05-15 |
Zucai SUO |
Substituted gemcitabine aryl amide analogs and treatment methods using same
|
|
EP2971033B8
(en)
|
2013-03-15 |
2019-07-10 |
ModernaTX, Inc. |
Manufacturing methods for production of rna transcripts
|
|
US10000521B2
(en)
|
2013-03-15 |
2018-06-19 |
Nucorion Pharmaceuticals, Inc. |
Substituted gemcitabine bicyclic amide analogs and treatment methods using same
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
CN103450301B
(zh)
*
|
2013-09-09 |
2015-09-09 |
南通大学 |
法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
|
|
WO2015051214A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
CN109414438A
(zh)
*
|
2016-06-28 |
2019-03-01 |
塞尔利克斯生物私人有限公司 |
用于治疗癌症的组合物和方法
|
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
WO2018129533A1
(en)
|
2017-01-09 |
2018-07-12 |
Shuttle Pharmaceuticals, Llc |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
CA3061621A1
(en)
|
2017-04-26 |
2018-11-01 |
Thomas I. Kalman |
Multitargeted nucleoside derivatives
|
|
US10435429B2
(en)
|
2017-10-03 |
2019-10-08 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouridine monophosphate cyclic triester compounds
|
|
US11407723B2
(en)
|
2018-01-09 |
2022-08-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
EP3752511A4
(en)
|
2018-01-10 |
2021-12-29 |
Nucorion Pharmaceuticals, Inc. |
Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
|
|
US11427550B2
(en)
|
2018-01-19 |
2022-08-30 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouracil compounds
|
|
CN111801339B
(zh)
*
|
2018-01-19 |
2025-06-24 |
纽科利制药公司 |
5-氟尿嘧啶化合物
|
|
US20210171564A1
(en)
*
|
2018-08-03 |
2021-06-10 |
Cellix Bio Provate Limited |
Compositions and methods for the treatment of cancer
|
|
CN109651467A
(zh)
*
|
2019-01-15 |
2019-04-19 |
齐鲁天和惠世制药有限公司 |
一种卡培他滨杂质及其制备方法
|
|
MX2022000573A
(es)
|
2019-07-17 |
2022-02-10 |
Nucorion Pharmaceuticals Inc |
Compuestos ciclicos de desoxirribonucleotido.
|
|
KR20230004716A
(ko)
|
2020-04-21 |
2023-01-06 |
리간드 파마슈티칼스 인코포레이티드 |
뉴클레오티드 프로드러그 화합물
|
|
JP2023535225A
(ja)
|
2020-07-24 |
2023-08-16 |
ストランド セラピューティクス インコーポレイテッド |
改変ヌクレオチドを含む脂質ナノ粒子
|
|
MX2023008002A
(es)
|
2021-01-08 |
2023-08-25 |
|
Constructos de expresion y usos de estos.
|
|
IL316186A
(en)
|
2022-04-26 |
2024-12-01 |
Strand Therapeutics Inc |
Lipid nanoparticles containing Venezuelan equine encephalitis (VEE) replicon and uses thereof
|
|
WO2025193628A2
(en)
|
2024-03-09 |
2025-09-18 |
Aadigen, Llc |
Compositions for treating cancer with kras mutations and uses thereof
|